PDS Biotechnology (PDSB) Net Cash Flow (2014 - 2025)
PDS Biotechnology's (PDSB) quarterly Net Cash Flow came in at $513317.0 in Q4 2025, up 106.37% YoY from $248739.4 in Q4 2024, and up 109.05% on a QoQ basis from -$5.7 million in Q3 2025.
PDS Biotechnology (PDSB) Net Cash Flow (2014 - 2025) Analysis & Trends
PDS Biotechnology (PDSB) has 12 years of Net Cash Flow data on file, last reported at $513317.0 in Q4 2025.
- Quarterly Net Cash Flow rose 106.37% year-over-year to $513317.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$15.0 million (down 0.91% YoY) and the FY2025 annual result came in at -$15.0 million, down 0.72% from the prior year.
- Net Cash Flow climbed to $513317.0 in Q4 2025, from -$5.7 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $49.7 million in Q2 2021 to a low of -$8.9 million in Q2 2024.
- A 5-year average of -$104929.8 and a median of -$4.8 million in 2021 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2021 — Net Cash Flow surged 1311.51% — and 2024, when it sank 449.12%.
- Tracing PDSB's Net Cash Flow over 5 years: stood at -$4.5 million in 2021, then jumped by 148.38% to $2.2 million in 2022, then increased by 6.03% to $2.3 million in 2023, then slumped by 449.12% to -$8.1 million in 2024, then soared by 106.37% to $513317.0 in 2025.
- The last three Net Cash Flow figures came in at $513317.0 (Q4 2025), -$5.7 million (Q3 2025), and -$8.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 225.59 Mn |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 513,317.00 |
| Dec 31, 2025 | 513,317.00 |
| Sep 30, 2025 | -5.67 Mn |
| Sep 30, 2025 | -5.67 Mn |
| Jun 30, 2025 | -8.11 Mn |
| Jun 30, 2025 | -8.11 Mn |
| Mar 31, 2025 | -1.71 Mn |
| Mar 31, 2025 | -1.71 Mn |
| Dec 31, 2024 | -8.06 Mn |
| Dec 31, 2024 | -8.06 Mn |
| Sep 30, 2024 | -7.98 Mn |
| Sep 30, 2024 | -7.98 Mn |
| Jun 30, 2024 | -8.87 Mn |
| Jun 30, 2024 | -8.87 Mn |
| Mar 31, 2024 | 10.07 Mn |
| Mar 31, 2024 | 10.07 Mn |
| Dec 31, 2023 | 2.31 Mn |
| Dec 31, 2023 | 2.31 Mn |
| Sep 30, 2023 | -6.37 Mn |
| Sep 30, 2023 | -6.37 Mn |